[1] |
Guo Y, Li P, Tang J, et al. Prevalence of atopic dermatitis in Chinese children aged 1-7 ys[J]. Sci Rep, 2016,6:29751. doi: 10.1038/srep29751.
|
[2] |
Hanifin JM, Rajka G. Diagnostic features of atopic dermatitis[J]. Acta Derm Venereol, 1980,60:44⁃47.
|
[3] |
赵辨. 湿疹面积及严重度指数评分法[J]. 中华皮肤科杂志, 2004,37(1):3⁃4.
|
[4] |
Simpson EL, Tom WL, Bushmakin AG, et al. Relationship among treatment, pruritus, investigator′s static global assessment, and quality of life in patients with atopic dermatitis[J]. Dermatol Ther (Heidelb), 2021,11(2):587⁃598. doi: 10.1007/s13555⁃021⁃00506⁃y.
|
[5] |
Yosipovitch G, Reaney M, Mastey V, et al. Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate⁃to⁃severe atopic dermatitis[J]. Br J Dermatol, 2019,181(4):761⁃769. doi: 10. 1111/bjd.17744.
|
[6] |
Lewis⁃Jones MS, Finlay AY, Dykes PJ. The infants′ dermatitis quality of life index[J]. Br J Dermatol, 2001,144(1):104⁃110. doi: 10.1046/j.1365⁃2133.2001.03960.x.
|
[7] |
Lewis⁃Jones MS, Finlay AY. The Children′s Dermatology Life Quality Index (CDLQI): initial validation and practical use[J]. Br J Dermatol, 1995,132(6):942⁃949. doi: 10.1111/j.1365⁃2133. 1995.tb16953.x.
|
[8] |
Cheape AC, Murrell DF. 2% crisaborole topical ointment for the treatment of mild⁃to⁃moderate atopic dermatitis[J]. Expert Rev Clin Immunol, 2017,13(5):415⁃423. doi: 10.1080/1744666X.2017. 1304820.
|
[9] |
Zebda R, Paller AS. Phosphodiesterase 4 inhibitors[J]. J Am Acad Dermatol, 2018,78(3 Suppl 1):S43⁃S52. doi: 10.1016/j.jaad.2017.11.056.
|
[10] |
Paller AS, Tom WL, Lebwohl MG, et al. Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults[J]. J Am Acad Dermatol, 2016,75(3):494⁃503.e6. doi: 10.1016/j.jaad.2016.05.046.
|
[11] |
Ma L, Zhang L, Kobayashi M, et al. Efficacy and safety of crisaborole ointment in Chinese and Japanese patients aged ≥2 years with mild⁃to⁃moderate atopic dermatitis[J]. J Dermatol, 2023,50(7):847⁃855. doi: 10.1111/1346⁃8138.16792.
|
[12] |
Yosipovitch G, Gold LF, Lebwohl MG, et al. Early relief of pruritus in atopic dermatitis with crisaborole ointment, a non⁃steroidal, phosphodiesterase 4 inhibitor[J]. Acta Derm Venereol, 2018,98(5):484⁃489. doi: 10.2340/00015555⁃2893.
|
[13] |
Eichenfield LF, Gower RG, Xu J, et al. Once⁃daily crisaborole ointment, 2%, as a long⁃term maintenance treatment in patients aged ≥ 3 months with mild⁃to⁃moderate atopic dermatitis: a 52⁃week clinical study[J]. Am J Clin Dermatol, 2023,24(4):623⁃635. doi: 10.1007/s40257⁃023⁃00780⁃w.
|
[14] |
Schlessinger J, Shepard JS, Gower R, et al. Safety, effectiveness, and pharmacokinetics of crisaborole in infants aged 3 to < 24 months with mild⁃to⁃moderate atopic dermatitis: a phase Ⅳ open⁃label study (CrisADe CARE 1)[J]. Am J Clin Dermatol, 2020,21(2):275⁃284. doi: 10.1007/s40257⁃020⁃00510⁃6.
|
[15] |
Eichenfield LF, Call RS, Forsha DW, et al. Long⁃term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis[J]. J Am Acad Dermatol, 2017,77(4):641⁃649.e5. doi: 10.1016/j.jaad.2017.06.010.
|
[16] |
Callender VD, Alexis AF, Stein Gold LF, et al. Efficacy and safety of crisaborole ointment, 2%, for the treatment of mild⁃to⁃moderate atopic dermatitis across racial and ethnic groups[J]. Am J Clin Dermatol, 2019,20(5):711⁃723. doi: 10.1007/s40257⁃019⁃00450⁃w.
|